Clinical Report: Everest Expands Ophthalmology Portfolio in China
Overview
Everest Medicines has entered an agreement to develop LNZ100, a once-daily eye drop for presbyopia, across Greater China. This therapy, known as VIZZ in the US, is designed to improve near vision by inducing pupil constriction without impairing distance vision.
Background
Presbyopia, a condition affecting near vision, typically begins around age 38 and has nearly 100% prevalence by age 52 in China. Current treatment options are limited, with no approved pharmacologic therapies available in the region. The introduction of LNZ100 aims to address this unmet clinical need.
Data Highlights
The China New Drug Application (NDA) acceptance is supported by a Phase 3 multicenter, randomized, double-blind, vehicle-controlled trial involving 300 participants. LNZ100 met the primary and key secondary endpoints, with statistically significant three-line or greater improvements in near best-corrected distance visual acuity while maintaining distance vision.
Key Findings
- Everest Medicines has signed an asset purchase agreement with Corxel Pharmaceuticals for LNZ100.
- LNZ100 is a 1.44% aceclidine ophthalmic solution aimed at treating presbyopia.
- The drug is designed to induce miosis without overstimulating the ciliary muscle, thus preserving distance vision.
- The therapy was approved in the US in July 2025 and is expected to receive NMPA approval in China in early 2027.
- Current treatment options for presbyopia in China are limited, with no pharmacologic eye drops approved.
Clinical Implications
The development of LNZ100 represents a potential new treatment option for presbyopia in China, addressing a significant gap in available therapies. Clinicians should be aware of this emerging option as it may enhance patient care for those affected by presbyopia.
Conclusion
The expansion of Everest's ophthalmology portfolio with LNZ100 highlights the ongoing efforts to provide innovative solutions for presbyopia in Greater China.
Related Resources & Content
- Optometric Management, 2023 -- Explain the Earliest Symptoms of Presbyopia
- Contact Lens Spectrum, 2022 -- NEWS SPECTRUM Recommendations
- Contact Lens Spectrum, 2022 -- NEWS SPECTRUM Recommendations
- Optometric Management, 2023 -- Maintain a consistent style on Instagram and TikTok
- FDA Label, 2025 -- Aceclidine 1.44% (VIZZ)
- label
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
